Companies Profiled in Genetic Testing Market are QIAGEN, 23andMe, Cepheid, Abbott Molecular Inc., Roche Diagnostics Middle East

Technological advancement in genetic testing is expected to drive the genetic testing market during the coming years. The demand for genetic testing is increasing across the globe owing to the availability of new tests as well as advancement in the genetic testing techniques. Innovations in tests that offer safer and efficient techniques of disease detection, surpassing the risk of miscarriage during early stages of pregnancy will serve to be a high impact rendering factor that will drive the genetic testing market growth during the forthcoming years.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/2490

Diagnostic testing segment accounted for the highest market share with a revenue share of USD 5690.6 million and is expected to grow at a significant rate over the forecast timeframe owing to its wide applications in various diseases. Detection of diseases at early stage allow patients to undergo therapeutic treatment at an early stage and minimizes the severity of diseases leading to reduced mortality rate. Increasing prevalence of chronic diseases worldwide will augment the segment growth over the forecast period.

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
• QIAGEN
• 23andMe
• Cepheid
• Abbott Molecular Inc.
• Roche Diagnostics Middle East
• Luminex Corporation
• Natera
• Myriad Genetics
• Counsyl
• MolecularMD
• Genomic Health
• Sequenom
• Genentech
• Bayer Diagnostics
• Biocartis
• bioMérieux
• Celera Genomictree Inc.
• HTG Molecular Diagnostics
• IntegraGen
• LabCorp Diagnostic Laboratories
• Pathway Genomics Corporation

Cardiovascular disease diagnosis segment of genetic testing market will grow at the fastest CAGR of nearly12.8% owing to rising prevalence of cardiac diseases across the globe. Genetic testing allows testing for a wide range of cardiovascular diseases (CVDs) encompassing congenital heart malformations. Timely diagnosis of heart disorders helps save lives and reduce the number of CVD deaths. Healthcare system’s efforts towards reducing CVD incidences should fuel business growth over the forecast period.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/2490

North America dominated the genetic testing market with a revenue of USD 6382.1 million in 2017 and is projected to grow at a significant rate over the forecast period. This is attributable to increasing incidences genetic diseases such as cancer, Turner syndrome, neurofibromatosis, and spinal muscular atrophy. Availability of new tests owing to technological advancements will fuel the demand for genetic testing. Advanced infrastructure coupled with high healthcare expenditure and regulatory support for direct-to-consumer genetic testing will further augment the market growth in the coming years.

Genetic Testing Market by Test type
o Predictive Testing
o Carrier Testing
o Prenatal And Newborn Testing
o Diagnostic Testing
o Pharmacogenomic Testing

Genetic Testing Market by Application
o Cancer Diagnosis
o Genetic Disease Diagnosis
o Cardiovascular Disease Diagnosis

Global Market Insights Inc. is a global market research and management consulting company catering to leading corporations, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

Global Market Insights, Inc.
4 North Main Street
Selbyville, Delaware 19975 USA
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email:sales@gminsights.com

This release was published on openPR.